Friday 6 November 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue: +13.3%
EPS: −51.5%
Free cash flow: +364.6%
Total debt: −4.00%

Quarter to September 2026, against a year earlier

Dividend growth 5 yrs

67.22 0.35 −0.52%

Follow RPRX

Alert me

Market cap: $39.0B
P/E: 44.8×
Fwd P/E: 27.3×
Dividend yield: 1.37%
F-score: 5/9
Altman Z: 1.61
Beneish M: −2.83
Dividend safety: 41/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Royalty Pharma PLC (RPRX) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Royalty Pharma PLC (RPRX) trades at a P/S ratio of 11.5×. Over the past ten years it has ranged from 0.0× (June 2020) to 11.5× (November 2026) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RPRX/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Royalty Pharma PLC P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RPRX/metrics/ps-ratio">Royalty Pharma PLC (RPRX) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	7.0×	38.26%
FY2024	5.1×	(6.01%)
FY2023	5.4×	(30.32%)
FY2022	7.7×	6.83%
FY2021	7.2×	(18.46%)
FY2020	8.9×	—
FY2019	0.0×	—
FY2018	0.0×	—

Period	P/S ratio	Change
Sep 2026	9.9×	1.09%
Jun 2026	9.8×	14.62%
Mar 2026	8.6×	22.94%
Dec 2025	7.0×	7.70%
25 more quarters	Free account

Against its own ten years

Low 0.0× High 11.5×

Ten-year median 7.1×

Current reading's percentile 100

Company	P/S ratio
INCY Incyte Corporation compare	4.0×
ONC BeOne Medicines Ltd. - Sponsored ADR compare	6.6×
GMAB Genmab A/S Sponsored ADR compare	7.9×
BNTX BioNTech SE Sponsored ADR compare	7.9×
ARGX argenex SE compare	9.5×
RPRX Royalty Pharma PLC	11.5×
INSM Insmed, Inc. compare	15.6×
RVMD Revolution Medicines, Inc. compare	185×
ROIV Roivant Sciences Ltd. compare	3,528×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Royalty Pharma PLC (RPRX) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on RPRX

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on RPRX

Stockrow Weekly